Der er også øget risiko for systemiske bivirkninger ved samtidig brug af fluticasonpropionat og andre potente CYP3A- hæmmere (se pkt.
Co-treatment with other potent CYP3A inhibitors, such as itraconazole, is also expected to increase the systemic fluticasone propionate exposure and the risk of systemic side-effects.